DCPH - Deciphera Pharma to undergo corporate restructuring; cuts workforce and ends program

Deciphera Pharmaceuticals (NASDAQ:DCPH) will undergo a corporate restructuring that will result in the elimination of 35% of its workforce and the ending a phase 1/2 program for solid tumors. The company said it will focus resources on two candidates, vemseltinib and DCC-3116. The former is in phase 1/2 for tenosynovial giant cell tumor and the latter in phase 1 for RAS/RAF mutant cancers in combination with Mekinist (trametinib). Deciphera is also streamlining its U.S. commercial operations. The company will keep a limited commercial presence in Europe for commercialization of Qinlock (ripretinib) in France and Germany. Qinlock is approved in the U.S. as a fourth-line treatment for gastrointestinal stromal tumors. The rebastinib program, which was expected to enter a phase 3 study in patients with platinum-resistant ovarian cancer next year, has been discontinued. Deciphera said the changes will extend its cash runway into 2024. Read what Seeking Alpha contributor Galzus Research recently

For further details see:

Deciphera Pharma to undergo corporate restructuring; cuts workforce and ends program